Abstract
Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities). Epidemiological and clinical data show that there is an association between asbestos exposure and MM development, even if the exact mechanism whereby asbestos induces MM is unknown. The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.
Keywords: Mesothelioma, pathogenesis, biomarkers, cDNA array
Current Cancer Drug Targets
Title: Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Volume: 10 Issue: 1
Author(s): S. Crispi, I. Cardillo, E. P. Spugnini, G. Citro, S. Menegozzo and A. Baldi
Affiliation:
Keywords: Mesothelioma, pathogenesis, biomarkers, cDNA array
Abstract: Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities). Epidemiological and clinical data show that there is an association between asbestos exposure and MM development, even if the exact mechanism whereby asbestos induces MM is unknown. The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.
Export Options
About this article
Cite this article as:
Crispi S., Cardillo I., Spugnini P. E., Citro G., Menegozzo S. and Baldi A., Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets, Current Cancer Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/156800910790980232
DOI https://dx.doi.org/10.2174/156800910790980232 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Antisense Strategies
Current Molecular Medicine Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry